FIXX

Homology Medicines, Inc.

0.82 USD
+0.02 (+2.86%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Homology Medicines, Inc. stock is up 41.9% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 5 February’s closed higher than January.

About Homology Medicines, Inc.

Homology Medicines, Inc. focuses on transforming the lives of patients suffering from rare genetic diseases. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues.